Compare HYLN & CYBN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | HYLN | CYBN |
|---|---|---|
| Founded | 2018 | 2019 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Construction/Ag Equipment/Trucks | Pharmaceuticals and Biotechnology |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 299.2M | 298.9M |
| IPO Year | N/A | N/A |
| Metric | HYLN | CYBN |
|---|---|---|
| Price | $1.85 | $7.13 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 4 |
| Target Price | $5.00 | ★ $74.50 |
| AVG Volume (30 Days) | ★ 936.6K | 680.8K |
| Earning Date | 11-11-2025 | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $4,272,000.00 | N/A |
| Revenue This Year | $204.64 | N/A |
| Revenue Next Year | $253.90 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 124.55 | N/A |
| 52 Week Low | $1.11 | $4.81 |
| 52 Week High | $2.79 | $10.73 |
| Indicator | HYLN | CYBN |
|---|---|---|
| Relative Strength Index (RSI) | 47.87 | 66.78 |
| Support Level | $1.76 | $6.53 |
| Resistance Level | $2.04 | $7.21 |
| Average True Range (ATR) | 0.10 | 0.40 |
| MACD | 0.00 | 0.13 |
| Stochastic Oscillator | 32.67 | 95.08 |
Hyliion Holdings Corp provides solutions that enable clean, flexible, and affordable electricity production. The Company focuses on delivering distributed power generators that can operate on various fuel sources to future-proof against an ever-changing energy economy. It is initially targeting the commercial and waste management industries with a locally deployable generator that can offer prime power as well as energy arbitrage opportunities. In addition to stationary power solutions, it focuses on mobile applications, including vehicles and marine technologies.
Cybin Inc is a biopharmaceutical company involved in creating safe and effective therapeutics for patients to address a multitude of mental health issues. The Company is a clinical-stage neuropsychiatric company focused on advancing therapies, delivery mechanisms, novel compounds, and protocols as potential treatments for various psychiatric and neurological conditions. The Company is developing technologies and delivery systems aimed at improving the pharmacokinetics of its proprietary molecules while retaining the therapeutic benefit. These new molecules and delivery systems are expected to be studied through clinical trials to confirm safety and efficacy.